Table S2. Patients’ groups according to resistance to crizotinib and PFS (36 evaluable patients).
Group | Definition | Patients, n (%) | Median PFS, months (95% CI) |
---|---|---|---|
Poor | Progression at first assessment | 6 (16.7) | 1.16 (0.13–1.90) |
Intermediate | Progression within 12 months | 17 (47.2) | 7.16 (2.87–11.63) |
Good | Progression ≥12 months or treatment ongoing | 13 (36.1) | 19.51 (12.33–28.90) |
PFS, progression-free survival; CI, confidence intervals.